Kyverna Therapeutics (KYTX) closed at $4.70 on November 17, 2026, down 1.3% from the previous close, on volume of 560,306 shares (30-day average 811,576).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 13-Nov 9:31 AM ET)
TipRanks (Fri, 13-Nov 1:01 AM ET)
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Thu, 12-Nov 12:12 PM ET)
Kyverna Therapeutics GAAP EPS of -$0.68 beats by $0.01
Seeking Alpha News (Thu, 12-Nov 8:37 AM ET)
Globe Newswire (Thu, 12-Nov 8:00 AM ET)
Business Wire (Wed, 11-Nov 1:32 PM ET)
Globe Newswire (Mon, 9-Nov 11:00 AM ET)
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Globe Newswire (Thu, 5-Nov 4:02 PM ET)
Globe Newswire (Fri, 23-Oct 10:30 AM ET)
Globe Newswire (Wed, 21-Oct 7:15 AM ET)
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Kyverna Therapeutics trades on the NASDAQ stock market under the symbol KYTX.
As of November 17, 2026, KYTX stock price declined to $4.70 with 560,306 million shares trading.
KYTX has a beta of 2.12, meaning it tends to be more sensitive to market movements. KYTX has a correlation of 0.16 to the broad based SPY ETF.
KYTX has a market cap of $297.14 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that KYTX belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.
KYTX has underperformed the market in the last year with a price return of -31.7% while the SPY ETF gained +10.1%. KYTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.5% and -10.0%, respectively, while the SPY returned -5.4% and -2.6%, respectively.
KYTX support price is $4.51 and resistance is $5.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYTX shares will trade within this expected range on the day.